Page last updated: 2024-11-05

monobutyl phthalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monobutyl phthalate (MBP) is an ester of phthalic acid, produced by the reaction of phthalic anhydride and n-butanol. It is a colorless, oily liquid with a faint odor. MBP is used as a plasticizer, mainly in polyvinyl chloride (PVC) products, to enhance their flexibility and durability. It can also be found in cosmetics, adhesives, and other industrial applications. While MBP is generally considered to be of low toxicity, some studies have linked it to potential adverse health effects, such as endocrine disruption, developmental toxicity, and reproductive toxicity. Furthermore, MBP is an environmental contaminant, often found in water, soil, and air. The persistence of MBP in the environment and its potential health effects have led to its inclusion in the list of chemicals of concern, prompting ongoing research into its environmental fate and human health risks.'

monobutyl phthalate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8575
CHEMBL ID2447930
CHEBI ID88522
SCHEMBL ID151027
MeSH IDM0091821

Synonyms (62)

Synonym
BIDD:PXR0137
1, monobutyl ester
131-70-4
nsc-8479
mono-n-butyl phthalate
butyl hydrogen phthalate
nsc8479
monobutyl phthalate
1,2-benzenedicarboxylic acid, monobutyl ester
brn 2051402
ai3-01768
einecs 205-036-2
nsc 8479
phthalic acid, monobutyl ester
2-(butoxycarbonyl)benzoic acid
NCGC00168325-01
mnbp
mono-n-butyl-phthalate
2-butoxycarbonylbenzoic acid
P1132
phthalic acid monobutyl ester
NCGC00168325-02
zi46lwz45g ,
unii-zi46lwz45g
1,2-benzenedicarboxylic acid, 1-butyl ester
tox21_300888
NCGC00254792-01
cas-131-70-4
dtxcid2020002
dtxsid4040002 ,
34-74-2
FT-0672456
mono-butyl phthalate
phthalic acid butyl ester
1,2-benzenedicarboxylic acid 1-butyl ester
FT-0623310
AG-205/06968036
AKOS015888413
S5826
CHEMBL2447930
chebi:88522 ,
SCHEMBL151027
2-(butoxycarbonyl)benzoic acid #
YZBOVSFWWNVKRJ-UHFFFAOYSA-N
phthalic acid mono-n-butyl ester
phthalic acid, butyl ester
1,2-benzenedicarboxylicacid,1-butyl ester
monobutylphthalate
mono-butyl phthalate, 97.0-103.0% (t)
mfcd00043498
mono-butyl phthalate, analytical standard
AS-65709
phthalic acid, mono-n-butyl ester
J-006038
-n-butyl-phthalate
2-(butoxycarbonyl)benzoate
Q26841330
D70341
butylhydrogenphthalate
CS-W013116
HY-N7143
phthalic acid, mono-n-butyl ester 100 microg/ml in methyl-tert-butyl ether

Research Excerpts

Overview

Monobutyl phthalate (MBP) is a primary metabolite of an environmental endocrine disruptor. MBP poses a potential threat to living organisms.

ExcerptReferenceRelevance
"Monobutyl phthalate (MBP) is a primary metabolite of an environmental endocrine disruptor dibutyl phthalate (DBP), which poses a potential threat to living organisms. "( Monobutyl phthalate (MBP) induces energy metabolism disturbances in the gills of adult zebrafish (Danio rerio).
Akindolie, MS; Jiao, Y; Qu, J; Tao, Y; Wang, L; Wu, S; Yang, Y; Zhang, Y; Zhu, G; Zhu, T, 2020
)
3.44

Toxicity

Monobutyl phthalate is a major metabolite of dibutylphthalate (DBP) The aim of this study was to assess the role of MBuP in the antiandrogenic effects of DBP.

ExcerptReferenceRelevance
"The objective of this study was to determine the adverse effects of monobutyl phthalate (MBuP), a major metabolite of dibutyl phthalate (DBP), on development of the reproductive system in offspring following maternal administration during late pregnancy, and to assess the role of MBuP in the antiandrogenic effects of DBP."( Adverse effects on development of the reproductive system in male offspring of rats given monobutyl phthalate, a metabolite of dibutyl phthalate, during late pregnancy.
Ema, M; Miyawaki, E,
)
0.59
" However, MBuP elicited a toxic effect at higher concentrations than DBP."( Effects of dibutyl phthalate and monobutyl phthalate on cytotoxicity and differentiation in cultured rat embryonic limb bud cells; protection by antioxidants.
Choi, YW; Han, SY; Kim, SH; Kim, SS; Kwack, SJ; Kwon, O; Lee, MK; Park, KL; Sohn, KH, 2002
)
0.6
" Monobutyl phthalate, the developmentally toxic metabolite of DBP, and its glucuronide conjugate were found in maternal and fetal plasma, amniotic fluid, and maternal urine."( Reproductive toxicity and pharmacokinetics of di-n-butyl phthalate (DBP) following dietary exposure of pregnant rats.
Dorman, DC; Gaido, KW; Hensley, JB; Lehmann, KP; Ross, SM; Sochaski, MA; Struve, MF; Willson, GA, 2009
)
1.26
"In search for alternative methods for developmental toxicity testing, we investigated whether embryonic stem cell (ESC) differentiation and its modulation by toxic exposure could be monitored by proteome profiling."( Proteome profiling of mouse embryonic stem cells to define markers for cell differentiation and embryotoxicity.
Blokland, M; Osman, AM; Pennings, JL; Piersma, AH; van Dartel, DA; Zwart, E, 2010
)
0.36
"Considering that research of adverse effects of mono(2-ethylhexyl) phthalate (MEHP) and monobutyl phthalate (MBP), two key metabolites of the most common phthalates used as plasticisers in various daily-life products, has been scattered and limited, the aim of our study was to provide a more comprehensive analysis by focusing on major organ systems, including blood, liver, kidney, and pancreas in 66 male pubertal rats randomised into eleven groups of six."( Endocrine adverse effects of mono(2-ethylhexyl) phthalate and monobutyl phthalate in male pubertal rats.
Barlas, N; Karabulut, G, 2022
)
1.18

Pharmacokinetics

ExcerptReferenceRelevance
" This study provides direct pharmacokinetic analysis for MBP and MBP-G in pregnant rats during fetal male reproductive development, and indicates that future pharmacokinetic or toxicology studies can reliably utilize oral dosing with DBP."( Pharmacokinetics of monobutylphthalate, the active metabolite of di-n-butylphthalate, in pregnant rats.
Borghoff, SJ; Kremer, JJ; Parkinson, HD; Williams, CC, 2005
)
0.33
" To evaluate the human risk of DBP, forward and reverse dosimetry was conducted using in silico simplified physiologically based pharmacokinetic (PBPK) modeling based on in vivo experimental pharmacokinetic data in humanized-liver mice (HL-mice) obtained after an oral dose of 100 mg/kg."( Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate.
Kamiya, Y; Miura, T; Mizuno, S; Murayama, N; Shimizu, M; Suemizu, H; Uehara, S; Yamazaki, H; Yoshizawa, M, 2019
)
0.78

Dosage Studied

ExcerptRelevanceReference
"The nature of products of contamination intake were investigated in cattle dosed with [14C]di-n-butylphthalate (DBP)."( Analysis of di-n-butylphthalate biotransformation in cattle by liquid chromatography/ion trap mass spectrometry/mass spectrometry.
Coldham, NG; Dave, M; Sauer, MJ, 1998
)
0.3
" In another experiment, pregnant dams were treated with DBP until gd 19, with the start of DBP treatment moved 1 d later into gestation for each treatment group, with the final group dosed only on gd 19."( Di(n-butyl) phthalate impairs cholesterol transport and steroidogenesis in the fetal rat testis through a rapid and reversible mechanism.
Gaido, KW; Ross, SM; Thompson, CJ, 2004
)
0.32
") dosing with MBP."( Pharmacokinetics of monobutylphthalate, the active metabolite of di-n-butylphthalate, in pregnant rats.
Borghoff, SJ; Kremer, JJ; Parkinson, HD; Williams, CC, 2005
)
0.33
" Previously, we reported dose-response associations of decreased semen quality with urinary concentrations of monobutyl phthalate (MBP) and monobenzyl (MBzP) phthalate, which are metabolites of dibutyl phthalate and butylbenzyl phthalate, respectively."( Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites.
Calafat, AM; Duty, S; Hauser, R; Meeker, JD; Silva, MJ, 2006
)
0.55
" Pregnant rats and neonatal male marmosets were dosed with 500 mg/kg/day DBP or MBP."( Effects of monobutyl and di(n-butyl) phthalate in vitro on steroidogenesis and Leydig cell aggregation in fetal testis explants from the rat: comparison with effects in vivo in the fetal rat and neonatal marmoset and in vitro in the human.
Anderson, RA; Bayne, R; Coutts, S; Greig, I; Hallmark, N; Mahood, IK; McKinnell, C; Morris, K; Scott, H; Sharpe, RM; Walker, M, 2007
)
0.34
" In order to gain a better understanding of the effect of repeated dosing on maternal and fetal metabolism and distribution, pregnant Sprague-Dawley rats were given a single dose of 500 mg/kg DBP on GD 19 or daily doses of 50, 100, and 500 mg/(kg day) from GD 12 to 19 via corn oil gavage."( Kinetics of selected di-n-butyl phthalate metabolites and fetal testosterone following repeated and single administration in pregnant rats.
Andersen, ME; Borghoff, SJ; Campbell, JL; Clewell, RA; Kremer, JJ; Sochaski, MA; Williams, CC, 2009
)
0.35
"Pregnant female marmosets were dosed from approximately 7-15 weeks gestation with 500 mg/kg/day MBP and male offspring studied at birth (1-5 days; n = 6) or in adulthood (n = 5)."( Effect of fetal or neonatal exposure to monobutyl phthalate (MBP) on testicular development and function in the marmoset.
Kelnar, CJ; McKinnell, C; Mitchell, RT; Morris, K; Sharpe, RM; Walker, M; Wallace, WH, 2009
)
0.62
" Overall, this study determined that the kinetics of the phthalate monoesters MEHP and MnBP after oral dosage are comparable to the properties of their diesters."( Kinetics of the phthalate metabolites mono-2-ethylhexyl phthalate (MEHP) and mono-n-butyl phthalate (MnBP) in male subjects after a single oral dose.
Fromme, H; Mittermeier, A; Völkel, W, 2016
)
0.43
" MBP dosed at 200 mg/kg significantly increased reactive oxygen species and malondialdehyde content in mouse testes."( Mono-butyl phthalate-induced mouse testis injury is associated with oxidative stress and down-regulated expression of Sox9 and Dazl.
Ding, S; Du, J; Li, X; Liu, X; Xiong, D; Yang, X; You, H; Yuan, J; Zhang, Q, 2017
)
0.46
" We constructed generalized linear regression models to examine the associations of medication intake with phthalate metabolite concentrations and dose-response relationships between the number of medicines used and metabolite concentrations in two matrices."( Associations between medication use and phthalate metabolites in urine and follicular fluid among women undergoing in vitro fertilization.
Deng, TR; Du, YY; Guo, N; Hua, X; Li, NJ; Li, YF; Liu, C; Teng, XM; Wu, LJ; Yao, YC; Yin, L; Yuan, XQ, 2021
)
0.62
" For developmental toxicity this requires scaling the in vitro observed dose-response characteristics to in vivo fetal exposure, while integrating maternal in vivo kinetics during pregnancy, in particular transplacental transfer."( Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
Fragki, S; Hoogenveen, R; Piersma, AH; Schwillens, P; van Oostrom, C; Zeilmaker, MJ, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phthalic acid monoesterA dicarboxylic acid monoester resulting from the formal condensation of an alcoholic or aromatic hydroxy group with just one of the two carboxy groups of phthalic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency72.65380.000714.592883.7951AID1259392
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.74460.000817.505159.3239AID1159527; AID1159531
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.34670.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency68.58960.000723.06741,258.9301AID743085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1364927Antiviral activity against Chikungunya virus KC969208 infected in African green monkey Vero cells after 48 hrs by MTT dye-based assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1364926Antiviral activity against Chikungunya virus KC969207 infected in African green monkey Vero cells after 48 hrs by MTT dye-based assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1364929Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus KC9692072017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1364930Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus KC9692082017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1364928Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (178)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.69)18.7374
1990's7 (3.93)18.2507
2000's41 (23.03)29.6817
2010's84 (47.19)24.3611
2020's43 (24.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.81 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.17%)5.53%
Reviews5 (2.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other175 (95.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]